VCCBH News

UVMCC Cancer Population Science Announces Pilot Award Grantees

May 28, 2024 by Katelyn Queen, PhD

Karlyn Martin, M.D. (left), and Jay Garvey, Ph.D. (right).

The Cancer Population Science research program at the University of Vermont Cancer Center recently announced the winners of its pilot awards. The pilot awards are a unique philanthropy-funded mechanisms to support members conducting population-based research. 

The awardees are:  

Karlyn Martin, M.D., associate professor of Medicine. Dr. Martin’s study will evaluate factors that influence initiating timely anticoagulation treatment in newly diagnosed pancreatic cancer patients. Individuals diagnosed with pancreatic cancer have a 50-fold higher chance of developing venous thromboembolism (VTE), or blood clots1. Despite guidelines which support starting newly diagnosed pancreatic cancer patients on anticoagulation medication, evidence indicates that this is not routinely done2. An inter-programmatic collaboration with Cancer Center members Chris Holmes, M.D. (CHE), Steven Ades, M.D. (CHE), and trainee member Ryan Thomas, this project will inform the development of effective implementation strategies for anticoagulation treatment, decreasing VTE in patients with pancreatic cancer and improving their outcomes. The project will evaluate factors across different settings, including rural areas, to ensure that implementation strategies reflect the needs of various groups within the Cancer Center’s catchment area. 

Jay Garvey, Ph.D., associate professor of Education. The pilot award will support studies on cancer-related health disparities among sexual and gender minority populations in rural Vermont. Vermont has approximately 5.2% of residents who identify as LGBTQIA+, ranking it as the sixth highest state in the nation3. Recent studies have shown substantial health disparities among sexual and gender minority communities4–7 (source). However, it is unclear how these communities are specifically impacted by cancer related health disparities. Working in collaboration with Kell Arbor from the Vermont PRIDE Center, Maija Reblin, Ph.D. (CPS), and Diego Adrianzen Herrera, M.D. (CHE), the team will explore cancer-related health disparities across the cancer continuum in rural Vermont. The findings of this study will inform future research directions and clinical care needs among sexual and gender minority communities. 

References:
1. Mulder, F. I. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137, 1959–1969 (2021).
2. Heffley, J. et al. Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma: Disease Burden and Initiation of Ambulatory Thromboprphylaxis.
3. LGBT Data & Demographics – The Williams Institute. https://williamsinstitute.law.ucla.edu/visualization/lgbt-stats/?topic=LGBT#about-the-data (2019).
4. Institute of Medicine. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. (The National Academies Press, Washington, DC, 2011).
5. Ceres, M., Quinn, G. P., Loscalzo, M. & Rice, D. Cancer Screening Considerations and Cancer Screening Uptake for Lesbian, Gay, Bisexual, and Transgender Persons. Semin. Oncol. Nurs. 34, 37–51 (2018).
6. Kamen, C. S. et al. “Treat us with dignity”: a qualitative study of the experiences and recommendations of lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer. Support. Care Cancer 27, 2525–2532 (2019).
7. Pratt-Chapman, M. L., Alpert, A. B. & Castillo, D. A. Health outcomes of sexual and gender minorities after cancer: a systematic review. Syst. Rev. 10, 183 (2021). 

Recent Stories and Publications Featuring VCCBH Members

Target ALS LinkedIn Post Featuring Research by Dr. Kathryn H. Morelli, PhD

Posted January 4, 2025

"ALS is a devastating disease, but researchers like Kathryn H. Morelli, Ph.D., a Target ALS Springboard Fellow and now an assistant professor at the University of Vermont, are driving innovations that bring us closer to effective treatments. Focused on developing RNA-targeted therapies for C9orf72 ALS, one of the most common genetic causes of the disease, Kathy’s work showcases the critical importance of collaboration, cutting-edge tools, and determination..."

Advancing ALS Research with Stem Cell Resources and Targeted Reagents: The Role of Target ALS in the Quest for Effective Treatment

Posted January 4, 2025

"ALS is a devastating neurodegenerative disease, and while there is no cure, ongoing research continues to offer hope for more effective treatments. An individual at the forefront of these efforts is Dr. Kathryn Morelli, an assistant professor in the Department of Neurological Sciences at the University of Vermont’s Larner College of Medicine, whose research aims to address the complex challenges of ALS, building on work she did with her postdoctoral mentor Dr. Gene Yeo. Working closely with Abby Kirch, a PhD student in her lab, Kathy and her team are focused on developing RNA-targeted therapies for ALS, particularly for the C9ORF72 mutation, one of the most common genetic causes of the disease..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted December 4, 2024

"On November 16, Larner Assistant Professor of Medicine Debora Kamin Mukaz, Ph.D., M.S., moderated a panel on science policy advocacy titled “How can we engage scientists from historically underrepresented backgrounds in policymaking and advocacy?” at the American Heart Association’s Scientific Sessions 2024 conference in Chicago. The panelists were AHA President Keith Churchwell, M.D.; past AHA President Michelle Albert, M.D., M.P.H.; Emelia Benjamin, M.D., Sc.M., associate provost and professor of medicine and epidemiology at Boston University; and Carl Streed, Jr., M.D., M.P.H., associate professor of medicine at Boston University..."

Research on spider brain leads to groundbreaking Alzheimer’s discovery

Posted December 3, 2024

"Neurodegeneration in spider brain leads Vermont neuroscientists to groundbreaking discovery in Alzheimer’s-affected human brains 
Vermont Business Magazine Researchers from Saint Michael’s College and the University of Vermont have made a groundbreaking new discovery that provides a better understanding of how Alzheimer’s disease develops in the human brain..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted October 23, 2024

"In a recent paper published in Nature Communications titled “Endothelial Piezo1 Channel Mediates Mechano-Feedback Control of Brain Blood Flow,” Osama Harraz, Ph.D., Bloomfield Early Career Professor in Cardiovascular Research and assistant professor of pharmacology at the Robert Larner, M.D. College of Medicine, and his team of researchers from American and European institutions reveal that Piezo1, a lesser-understood protein, acts as a “brake” system, helping blood flow return to normal after neural activity..."

The association of leptin and incident hypertension in the reasons for geographic and racial differences in stroke (REGARDS) cohort

Posted October 23, 2024

"Leptin is an adipokine associated with obesity and with hypertension in animal models. Whether leptin is associated with hypertension independent of obesity is unclear. Relative to White adults, Black adults have higher circulating leptin concentration..."

Assessing prenatal and early childhood social and environmental determinants of health in the HEALthy Brain and Child Development Study (HBCD)

Posted October 23, 2024

"The HEALthy Brain and Child Development (HBCD) Study, a multi-site prospective longitudinal cohort study, will examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally and planned through early childhood..."

Health Watch: UVM researchers unlock secrets of brain blood flow in cognitive health

Posted October 16, 2024

"Osama Harraz, Ph.D and his team of researchers at the University of Vermont’s Larner College of Medicine have made a breakthrough that could help in the effort to better understand the causes of dementia and how to stop it..."